Fibroblast growth factor is associated to left ventricular mass index, anemia and low values of transferrin saturation

Eser, Barış; Yayar, Özlem; Buyukbakkal, Mehmet; Erdoğan, Bülent; Ercan, Zafer; Merhametsiz, Özgür; Haspulat, Ayhan; Oğuz, Ebru Gök; Doğan, İbrahim; Canbakan, Başol; Aylı, Mehmet Deniz

doi:10.1016/j.nefro.2015.06.025

Cited by 11 publications

(8 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…24 In another study conducted in peritoneal dialysis patients, patients with high sFGF-23 level had lower hemoglobin and transferrin saturation, and they used more recombinant erythropoietin. 25 Our study results support an inverse relation between iron deficiency and FGF-23 both in the normal population and the early stages of ADPKD.…”

Section: Discussionsupporting

confidence: 83%

Erken Evre Otozomal Dominant Polikistik Böbrek Hastalığında; FGF-23 İnfamasyon ve Demir Metabolizması

Doğan

Ocak

Eser

et al. 2019

Osmangazi̇ Journal of Medicine

View full text Add to dashboard Cite

To investigate the correlation of Fibroblast Growth Faktör-23 (sFGF-23) with iron status, inflammation and carotid intima-media thickness (CIMT) in the early stages of autosomal dominant polycystic kidney disease (ADPKD). Forty ADPKD patients (24 female) with normal creatinine levels and 40 healthy volunteers (21 female) were included in the study. Serum FGF-23 levels were measured using the ELISA technique. The associations between sFGF-23 with CIMT, hs-CRP, neutrophil lymphocyte ratio (NLR) and iron parameters were evaluated using correlation analysis. Patients' sFGF-23 levels were significantly higher [245 (182-963) pg/mL; vs. 219.6 (34-494) pg/mL], (P< 0.001). NLR and hs-CRP were also found to be statistically higher in patients than controls (P< 0.001 and P= 0.003, respectively). CIMT was significantly higher in the patient group (P= 0.037). There were statistically significant negative correlations between sFGF-23 and calcium, hemoglobin, hematocrit, serum iron, ferritin, and NLR (P= 0.009, P= 0.035, P= 0.002, P= 0.033, P= 0.017, P= 0.023, respectively), and positive correlations with phosporus, total iron binding capacity and sFGF-23 (P= 0.010, P= 0.049, respectively). There was no statistically significant correlation between sFGF-23 and PTH, hs-CRP and CIMT. In multivariate lineer regression analysis, serum phosphorus level was statistically significiant independent risk factor for the determinantion of sFGF-23 level [B: 0.318, OR:130,662(32,715-228,610), P=0.010]. Our study results support an inverse relationship between sFGF-23 and iron deficiency but no relationship between sFGF-23 and inflammation and atherosclerosis in the early stages of ADPKD.

show abstract

Section: Discussionsupporting

confidence: 83%

Erken Evre Otozomal Dominant Polikistik Böbrek Hastalığında; FGF-23 İnfamasyon ve Demir Metabolizması

Doğan

Ocak

Eser

et al. 2019

Osmangazi̇ Journal of Medicine

View full text Add to dashboard Cite

show abstract

“…showed no significant relationship between FGF23 and hemoglobin levels in 282 patients undergoing hemodialysis 27 . These findings were contradicted by two other studies: one on patients undergoing peritoneal dialysis and one on patients with CKD before dialysis treatment 21 , 22 . These studies showed a significant inverse association between FGF23 and anemia.…”

Section: Discussionmentioning

confidence: 82%

Circulating Fibroblast Growth Factor-23 Levels are Associated with an Increased Risk of Anemia Development in Patients with Nondialysis Chronic Kidney Disease

Nam

Kim

et al. 2018

Sci Rep

View full text Add to dashboard Cite

Fibroblast growth factor-23 (FGF23) is an established biomarker of adverse outcomes in patients with chronic kidney disease (CKD). Several cross-sectional studies have suggested a possible association between FGF23 and anemia in these patients. In this large-scale prospective cohort study, we investigated this relationship and examined whether high FGF23 levels increase the risk of incident anemia. This prospective longitudinal study included 2,089 patients from the KoreaN cohort study for Outcome in patients With CKD. Anemia was defined as hemoglobin level <13.0 g/dl (men) and <12.0 g/dl (women). Log-transformed FGF23 significantly correlated with hepcidin but inversely correlated with iron profiles and hemoglobin. Multivariate logistic regression showed that log-transformed FGF23 was independently associated with anemia (odds ratio [OR], 1.14; 95% confidence interval [CI], 1.04–1.24, P = 0.01). Among 1,164 patients without anemia at baseline, 295 (25.3%) developed anemia during a median follow-up of 21 months. In fully adjusted multivariable Cox models, the risk of anemia development was significantly higher in the third (hazard ratio [HR], 1.66; 95% CI, 1.11–2.47; P = 0.01) and fourth (HR, 1.84; 95% CI, 1.23–2.76; P = 0.001) than in the first FGF23 quartile. In conclusion, high serum FGF23 levels were associated with an increased risk for anemia in patients with nondialysis CKD.

show abstract

“…Clinical investigations have demonstrated significant associations between increased serum FGF23 levels, the longitudinal decline in hemoglobin levels and the overall risk incidence of anemia [158,307]. Furthermore, recent studies have displayed an inverse correlation with transferrin saturation levels, serum iron levels and erythropoiesis [112,308,309,310]. The pleiotropic actions of FGF23, along with its functional impact in renal anemia, have been ascribed to direct and indirect mechanisms (Figure 4).…”

Section: Direct and Indirect Actions Of Fgf23 In Anemiamentioning

confidence: 99%

The Role of Fibroblast Growth Factor 23 in Inflammation and Anemia

Czaya

Faul

2019

IJMS

View full text Add to dashboard Cite

In patients with chronic kidney disease (CKD), adverse outcomes such as systemic inflammation and anemia are contributing pathologies which increase the risks for cardiovascular mortality. Amongst these complications, abnormalities in mineral metabolism and the metabolic milieu are associated with chronic inflammation and iron dysregulation, and fibroblast growth factor 23 (FGF23) is a risk factor in this context. FGF23 is a bone-derived hormone that is essential for regulating vitamin D and phosphate homeostasis. In the early stages of CKD, serum FGF23 levels rise 1000-fold above normal values in an attempt to maintain normal phosphate levels. Despite this compensatory action, clinical CKD studies have demonstrated powerful and dose-dependent associations between FGF23 levels and higher risks for mortality. A prospective pathomechanism coupling elevated serum FGF23 levels with CKD-associated anemia and cardiovascular injury is its strong association with chronic inflammation. In this review, we will examine the current experimental and clinical evidence regarding the role of FGF23 in renal physiology as well as in the pathophysiology of CKD with an emphasis on chronic inflammation and anemia.

show abstract

Fibroblast growth factor is associated to left ventricular mass index, anemia and low values of transferrin saturation

Abstract: FGF-23 is associated with LVMI, anemia and low TSAT in patients with PD. Whether increased FGF-23 is a marker or a potential mechanism of myocardial hypertrophy and anemia in patients with end-stage renal disease (ESRD) requires further study.

Cited by 11 publications

References 53 publications

Erken Evre Otozomal Dominant Polikistik Böbrek Hastalığında; FGF-23 İnfamasyon ve Demir Metabolizması

Erken Evre Otozomal Dominant Polikistik Böbrek Hastalığında; FGF-23 İnfamasyon ve Demir Metabolizması

Circulating Fibroblast Growth Factor-23 Levels are Associated with an Increased Risk of Anemia Development in Patients with Nondialysis Chronic Kidney Disease

The Role of Fibroblast Growth Factor 23 in Inflammation and Anemia

Contact Info

Product

Resources

About